4DMT to Use $75 Million Series C to Advance Three Key Pipeline Products

California-based 4D Molecular Therapeutics (4DMT) announced today that it has concluded a $75 million Series C round of financing, led by Viking Global Investors. Proceeds from the funding round will be used to advance three of the company’s precision-guided AAV gene therapy product candidates through initial clinical proof-of-concept in patients.